Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases

Manxiang Wu; Chengyuan Hong; Chunjuan Shen; Dong Xie; Tianxiang Chen; Aiguo Wu; Qiang Li

doi:10.1080/10717544.2023.2289846

Drug Delivery (Dec 2023)

Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases

Manxiang Wu,
Chengyuan Hong,
Chunjuan Shen,
Dong Xie,
Tianxiang Chen,
Aiguo Wu,
Qiang Li

Affiliations

Manxiang Wu: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo, China
Chengyuan Hong: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo, China
Chunjuan Shen: Center for Reproductive Medicine, Jiaxing University Affilated Maternity and Child Hospital, Jiaxing, P. R. China
Dong Xie: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo, China
Tianxiang Chen: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo, China
Aiguo Wu: Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Ningbo, China
Qiang Li: Department of Radiology, The Affiliated People’s Hospital of Ningbo University, Ningbo, P. R. China

DOI: https://doi.org/10.1080/10717544.2023.2289846
Journal volume & issue: Vol. 30, no. 1

Abstract

Read online

AbstractThe conventional treatment methods used for the management of autoimmune diseases (ADs) have limited efficacy and also exhibit significant side effects. Thus, identification of novel strategies to improve the efficacy and safety of ADs treatment is urgently required. Overactivated immune response and oxidative stress are common characteristics associated with ADs. Polydopamine (PDA), as a polymer material with good antioxidant and photothermal conversion properties, has displayed useful application potential against ADs. In addition, PDA possesses good biosafety, simple preparation, and easy functionalization, which is conducive for the pharmacological development of PDA nanomaterials with clinical transformation prospects. Here, we have first reviewed the preparation of PDA, the different functional integration strategies of PDA-based biomaterials, and their potential applications in ADs. Next, the mechanism of action of PDA in ADs has been elaborated in detail. Finally, the application opportunities and challenges linked with PDA nanomaterials for ADs treatment are discussed. This review is contributed to design reasonable and effective PDA nanomaterials for the diagnosis and treatment of ADs.

Published in Drug Delivery

ISSN: 1071-7544 (Print); 1521-0464 (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.tandfonline.com/journals/idrd

About the journal

Abstract

Keywords